[Urgent] Starlink Set For The Largest IPO In History?

He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again with Tesla… which is up more than 19,500% since 2010. For perspective, that turns $100 invested into almost $20,000! And now, Elon could be set to do it for the third and final time… with what might be his biggest breakthrough yet. And for the first time ever, you have the rare chance to profit BEFORE the upcoming IPO.

Click here now for the urgent details on this hidden play.

Dawn Rogers Biography and Net Worth

EVP of Pfizer

Dawn Rogers joined American Securities in 2021. She focuses on all aspects of human capital leadership and organizational design across the firm’s portfolio companies.

Prior to joining American Securities, Dawn was EVP and Chief Human Resources Officer at Pfizer. Her career with Pfizer spanned more than twenty years across their global business working as a key member of the executive team supporting growth and innovation of the organization. Previously, she was Senior Director of Human Resources at Kos Pharmaceuticals, where she established the human resources function and built their commercial organization in preparation for their first product launch and IPO. Prior to joining Kos Pharmaceuticals, Dawn held human resources positions at Earth Tech Inc. and The Ares Serono Group/Serono Diagnostics.

Dawn received a BA in Psychology/Human Resources from Moravian College and an MS in Management from Lesley University.

What is Dawn Rogers' net worth?: The estimated net worth of Dawn Rogers is at least $736,719.30 as of March 4th, 2019. Ms. Rogers owns 28,722 shares of Pfizer stock worth more than $736,719 as of November 23rd. This net worth approximation does not reflect any other assets that Ms. Rogers may own. Learn More about Dawn Rogers' net worth.
How do I contact Dawn Rogers?: The corporate mailing address for Ms. Rogers and other Pfizer executives is 235 EAST 42ND STREET, NEW YORK NY, 10017. Pfizer can also be reached via phone at (212) 733-2323. Learn More on Dawn Rogers' contact information.
Has Dawn Rogers been buying or selling shares of Pfizer?: Dawn Rogers has not been actively trading shares of Pfizer within the last three months. Most recently, Dawn Rogers sold 15,002 shares of the business's stock in a transaction on Monday, March 4th. The shares were sold at an average price of $42.98, for a transaction totalling $644,785.96. Following the completion of the sale, the executive vice president now directly owns 28,722 shares of the company's stock, valued at $1,234,471.56. Learn More on Dawn Rogers' trading history.
Who are Pfizer's active insiders?: Pfizer's insider roster includes Ronald Blaylock (Director), Albert Bourla (DVM), Loretta Cangialosi (VP), William Carapezzi, Jr. (EVP), Albert D.V.M. (DVM), Frank Damelio (EVP), Frank D'Amelio (CFO & Exec. VP ), Jennifer Damico (SVP), Jennifer Damico (SVP), Scott Gottlieb (Director), Rady Johnson (Insider), Douglas Lankler (EVP), Alexander Mackenzie (EVP), Laurie Olson (Insider), Ian Read (CEO), Dawn Rogers (EVP), Sally Susman (Insider), and John Young (Insider). Learn More on Pfizer's active insiders.
Are insiders buying or selling shares of Pfizer?: In the last year, Pfizer insiders bought shares 2 times. They purchased a total of 4,000 shares worth more than $107,650.00. The most recent insider tranaction occured on October, 30th when Director Scott Gottlieb bought 1,000 shares worth more than $28,240.00. Insiders at Pfizer own 0.1% of the company. Learn More about insider trades at Pfizer.
Information on this page was last updated on 10/30/2024.

Dawn Rogers Insider Trading History at Pfizer

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
3/4/2019	Sell	15,002	$42.98	$644,785.96	28,722

Dawn Rogers Buying and Selling Activity at Pfizer

Pfizer Company Overview

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Today's Range

Now: $25.65

$25.10

$25.75

50 Day Range

MA: $28.21

$24.80

$30.20

2 Week Range

Now: $25.65

$24.48

$31.54

Volume

41,896,988 shs

Average Volume

54,672,200 shs

Market Capitalization

$145.36 billion

P/E Ratio

34.66

Dividend Yield

6.69%

Beta

0.67